These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 27457257)

  • 1. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
    Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
    Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
    Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
    Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
    Liu JH; Medeiros FA; Slight JR; Weinreb RN
    Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
    Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
    J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
    Liu JH; Kripke DF; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
    Araie M; Sforzolini BS; Vittitow J; Weinreb RN
    Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
    Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
    Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.
    Konstas AG; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
    Am J Ophthalmol; 1999 Jul; 128(1):15-20. PubMed ID: 10482089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
    Hoy SM
    Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.
    Rácz P; Ruzsonyi MR; Nagy ZT; Gaygi Z; Bito LZ
    Arch Ophthalmol; 1996 Mar; 114(3):268-73. PubMed ID: 8600885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
    Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peak pressures: crossover study of timolol and latanoprost.
    Sihota R; Saxena R; Agarwal HC; Pandey RM; Gulati V
    Eur J Ophthalmol; 2003 Jul; 13(6):546-52. PubMed ID: 12948313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure.
    Seibold LK; Kahook MY
    Am J Ophthalmol; 2014 Jan; 157(1):44-49.e1. PubMed ID: 24182742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
    Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
    Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.